85 related articles for article (PubMed ID: 21573528)
21. Transforming growth factor-beta in in vivo resistance.
Teicher BA; Holden SA; Ara G; Chen G
Cancer Chemother Pharmacol; 1996; 37(6):601-9. PubMed ID: 8612316
[TBL] [Abstract][Full Text] [Related]
22. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.
Chatterjee D; Liu CJ; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1995; 35(5):423-31. PubMed ID: 7850925
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
25. Lisofylline as an adjuvant to high dose cytotoxic therapy.
Teicher B; Kakeji Y; Northey D
Int J Oncol; 1997 Aug; 11(2):265-72. PubMed ID: 21528210
[TBL] [Abstract][Full Text] [Related]
26. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
27. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells.
Hixson LJ; Alberts DS; Krutzsch M; Einsphar J; Brendel K; Gross PH; Paranka NS; Baier M; Emerson S; Pamukcu R
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):433-8. PubMed ID: 7920212
[TBL] [Abstract][Full Text] [Related]
29. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
Teicher BA; Holden SA; Ara G; Korbut T; Menon K
Cancer Chemother Pharmacol; 1996; 38(2):169-77. PubMed ID: 8616908
[TBL] [Abstract][Full Text] [Related]
30. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
31. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
32. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
33. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
34. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
Frei E; Holden SA; Gonin R; Waxman DJ; Teicher BA
Cancer Chemother Pharmacol; 1993; 33(2):113-22. PubMed ID: 8261570
[TBL] [Abstract][Full Text] [Related]
35. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.
Graham CH; Kobayashi H; Stankiewicz KS; Man S; Kapitain SJ; Kerbel RS
J Natl Cancer Inst; 1994 Jul; 86(13):975-82. PubMed ID: 8007019
[TBL] [Abstract][Full Text] [Related]
36. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.
Croix BS; Rak JW; Kapitain S; Sheehan C; Graham CH; Kerbel RS
J Natl Cancer Inst; 1996 Sep; 88(18):1285-96. PubMed ID: 8797768
[TBL] [Abstract][Full Text] [Related]
37. The proteasome inhibitor PS-341 in cancer therapy.
Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
